A federal district judge last week declined to make federal health officials give a South Carolina health center any more documents linked to the center’s brief expulsion from and subsequent reinstatement to the 340B program in 2018.
U.S. Chief District
…
Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”
Groups that represent
…
Certain flexibilities to the 340B program allowed under the COVID-19 public health emergency will expire May 11 alongside the PHE, the U.S. Health Resources and Services Administration announced Monday.
The update, which HRSA posted prominently on the Office of Pharmacy
…
Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use
…
Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.
Covered entities reported receiving letters from Bayer about
…
An American Hospital Association senior executive told a U.S. House subcommittee yesterday her group opposes creating “significant new reporting requirements for 340B hospitals that do not reflect the true value or intent of the 340B program.”
But when asked by
…
The 340B program has evolved into a “buy low, sell high” drug pricing system abused by some hospitals that have profits as their main goal, a health policy researcher told lawmakers Wednesday at a U.S. House subcommittee hearing.
The House
…SPONSORED CONTENT
Many covered entities are not aware of the opportunity to capture referral prescriptions. This includes ones that were initially determined to be non-eligible by your TPA but after a closer look in your EMR are deemed to be eligible. Don’t miss out
…
The Louisiana House voted 97-2 yesterday to pass and send to the Senate legislation to stop drug manufacturer interference with 340B contract pharmacy arrangements. It also would prohibit pharmacy benefit manager and payor practices that lower reimbursement for 340B-purchased drugs.
…
With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.
Slafsky, publisher and CEO of 340B
…
×
*Sign up for news summaries and alerts from 340B Report
